NEW YORK, June 9, 2025 ~ Formation Bio, a leading AI-driven pharmaceutical company, has announced the appointment of its first class of Entrepreneurs in Residence (EIRs). The four seasoned dealmakers, Kia Motesharei, Ph.D., Minji Kim Ph.D, MBA, John Taylor, M.S., and Anthony S. Walsh, D.Phil, will work closely with Chief Business Officer David Steinberg to expand the company's business development capabilities and further its mission to accelerate drug development and bring high-potential treatments to patients faster.

Formation Bio is known for acquiring and in-licensing promising drug assets and advancing them through critical development milestones. Their AI platform supports this end-to-end process, from asset identification to execution of clinical trials. With the addition of the EIRs, Formation Bio aims to strengthen its pipeline through strategic partnerships and licensing deals.

The EIR program at Formation Bio offers a unique opportunity for experienced dealmakers to deploy capital through an innovative model. Each of the newly appointed EIRs brings extensive experience in sourcing and executing high-value biopharma transactions. This reflects Formation Bio's commitment to investing in growing its pipeline and unlocking value for patients.

More on Boston Chron

• Boston: Updates on Transformative Investments in Mental Health Services and Programs for Youth and Families
• AI changes cryptocurrency market trading, TWL Miner launches new 1-day contract, giving away over $1 million
• King Faisal Specialist Hospital & Research Centre and Germfree Laboratories Announce Landmark Advanced Therapy Manufacturing Campus in Riyadh
• Labthink's Medford Lab is Open for Testing Services for Flexible Packaging Materials
• A Global First: NaturismRE™ Launches the Global Urgency Index

According to David Steinberg, Chief Business Officer at Formation Bio, the biotech industry is at a crucial point where breakthrough science is abundant but funding and resources are scarce. He believes that Formation Bio can bridge this gap with its capital, drug development capabilities, model, and platform. Steinberg expresses his excitement about welcoming the EIRs and their ability to go deep on science they believe in and advance transformative medicines.

Combining proprietary technology with deep domain expertise, Formation Bio's teams uncover overlooked or underdeveloped promising programs to transact on and develop. The EIRs will play a crucial role in this work with their decades of dealmaking experience and industry connectivity. They will also bring their expertise in various therapeutic areas such as NASH/MASH, Korea/APAC, rare diseases, and immunology & inflammation (I&I).

The diverse focus areas of the EIRs will strengthen Formation Bio's ability to identify and unlock high-value opportunities across a wide range of modalities and markets. Their arrival also reflects the company's growing presence in key industry hubs like Boston and North Carolina, where they are deepening ties with leading talent, companies, and partners across the biotech and pharma ecosystem.

In conclusion, the appointment of these four highly experienced EIRs at Formation Bio highlights the company's commitment to accelerating drug development and bringing innovative treatments to patients. With their expertise and Formation Bio's AI platform, the company is well-positioned to make significant strides in the biotech industry.

---

Show All News | Report Violation